Literature DB >> 7723227

IgA nephropathy.

J H Galla1.   

Abstract

IgAN is the most common type of glomerulonephritis worldwide, and is found more in men and distinctly less in blacks. It presents with macroscopic hematuria in about 40 to 45% of patients, with microscopic hematuria and proteinuria in about 35 to 40%, and with nephrotic syndrome or acute renal failure in the remainder. The diagnosis continues to rely on the finding of the dominant or codominant mesangial deposition of IgA on immunohistologic examination of the kidney. No blood or urine test is sufficiently reliable for diagnosis. While the pathogenesis remains unknown, accumulating evidence suggests that polyclonal stimulation of immunoglobulins perhaps coupled with structural abnormalities of IgA play pivotal roles. These defects may account for the variety of autoantibodies detected in patients with both IgAN and HSP. While IgAN has an indolent course, about 30% of patients will reach ESRD after 20 years, particularly in those who present with hypertension, heavy proteinuria or renal insufficiency. At present, therapy is disappointing, but immunoglobulin supplementation and newer agents that interrupt the pathways of mesangial proliferation and sclerosis hold promise for the future. Kidney transplantation has shown excellent allograft survival.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7723227     DOI: 10.1038/ki.1995.50

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  68 in total

1.  Uteroglobin deficient mice-a novel animal model for IgA nephropathy?

Authors:  S Pouria; S J Challacombe
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

2.  Increase in tonsillar germinal centre B-1 cell numbers in IgA nephropathy (IgAN) patients and reduced susceptibility to Fas-mediated apoptosis.

Authors:  S Kodama; M Suzuki; M Arita; G Mogi
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

Review 3.  Progress in molecular and genetic studies of IgA nephropathy.

Authors:  J Novak; B A Julian; M Tomana; J Mesteck
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

4.  Polymorphism of the human alpha1 immunoglobulin gene 3' enhancer hs1,2 and its relation to gene expression.

Authors:  Y Denizot; E Pinaud; C Aupetit; C Le Morvan; E Magnoux; J C Aldigier; M Cogné
Journal:  Immunology       Date:  2001-05       Impact factor: 7.397

5.  Expression of T cell receptor variable region families by bone marrow gammadelta T cells in patients with IgA nephropathy.

Authors:  K S Buck; E M Foster; D Watson; J Barratt; I Z A Pawluczyk; J F Knight; J Feehally; A C Allen
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

6.  Oligoclonally expanding gammadelta T lymphocytes induce IgA switching in IgA nephropathy.

Authors:  S Toyabe; W Harada; M Uchiyama
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 7.  Dysfunctions of the Iga system: a common link between intestinal and renal diseases.

Authors:  Christina Papista; Laureline Berthelot; Renato C Monteiro
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

8.  Analysis of an expanded width of albumin fraction by cellulose acetate membrane electrophoresis in IgA nephropathy urine before treatment.

Authors:  Ryoko Machii; Kazuyuki Matsuda; Nobuo Hiratsuka; Kayo Sugimoto; Osamu Hotta; Yoshihisa Itoh; Hiroshi Yoshida; Kiyoko Shiba
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

9.  Adalimumab-induced IgA nephropathy.

Authors:  Aneesha Kaur Bhagat Singh; Andrew Sujeevan Jeyaruban; Gregory John Wilson; Dwarakanathan Ranganathan
Journal:  BMJ Case Rep       Date:  2019-03-31

10.  Role of hepatitis B virus infection in pathogenesis of IgA nephropathy.

Authors:  Nian-Song Wang; Zhao-Long Wu; Yue-E Zhang; Mu-Yi Guo; Lv-Tan Liao
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.